Alexion's Soliris wins $1B myasthenia gravis approval with broader-than-expected label

24th October 2017 Uncategorised 0

It took longer than some industry watchers expected, but Alexion has another indication for lead medication Soliris in the bag. On Monday, the company said the FDA had greenlighted the product to treat refractory generalized myasthenia gravis patients who are antiacetylcholine receptor antibody positive—a subset broader than the population treated in Alexion’s trial.

More: Alexion's Soliris wins B myasthenia gravis approval with broader-than-expected label
Source: fierce